Observational studyClinical rheumatology2017

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.

E M H Schmitz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.